US EditionPublished • loading... • Updated
Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
AK150 targets three immunomodulatory receptors to remodel the tumor microenvironment and showed dose-dependent tumor inhibition in preclinical models, addressing immunotherapy resistance.
- On March 15, 2026, Akeso, Inc. announced that its first-in-class trispecific antibody AK150 received Investigational New Drug clearance from China's National Medical Products Administration to begin clinical trials in patients with advanced solid tumors.
- Single- and dual-target macrophage therapies have failed to fully break the tumor microenvironment's immunosuppressive network, prompting demand for multi-target approaches that address ILT2, ILT4, and CSF1R simultaneously.
- Engineered via Akeso's AI-driven drug discovery platform and proprietary Tetrabody technology, AK150 depletes immunosuppressive myeloid cells while releasing "molecular brakes" on remaining populations. Preclinical animal models showed dose-dependent tumor inhibition across all tested dosage groups.
- If effective clinically, AK150 could convert "cold tumors" into "hot tumors," improving responsiveness to immunotherapy by coordinating innate and adaptive immune activation against suppressive myeloid networks.
- Akeso operates a pipeline of over 50 innovative assets, with 27 candidates in clinical trials and 7 marketed drugs. The company cautioned that forward-looking statements carry regulatory and clinical risks that could materially affect development outcomes.
Insights by Ground AI
41 Articles
41 Articles
The Berkshire Eagle+40 Reposted by 40 other sources
Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) for clinical…
Coverage Details
Total News Sources41
Leaning Left5Leaning Right6Center15Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 19%
C 58%
R 23%
Factuality
To view factuality data please Upgrade to Premium
